GlassScriptPhysician profile
Cory B Davidson
NPI 1235389412
$119,480.89
in general payments reported to CMS, 2019-2025
48 companies · $179 in 2025
The $179 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15K · 2022: $74K · 2023: $29K · 2024: $1,750 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,800 · Travel and Lodging: $6,641 · Food and Beverage: $3,436 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,430.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,800.00 |
| Travel and Lodging | $6,640.65 |
| Food and Beverage | $3,435.68 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $98,235.93 | 2021-2023 | Crysvita |
| Kyowa Kirin, INC. | $11,935.36 | 2023-2024 | Crysvita |
| Abbvie INC. | $2,523.08 | 2021-2023 | |
| Novo Nordisk INC | $1,855.16 | 2021-2024 | Sogroya, Wegovy, Saxenda |
| Dexcom, INC. | $802.65 | 2021-2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $635.04 | 2021-2024 | Jardiance, Lyumjev, Baqsimi |
| Sanofi-Aventis U.S. LLC | $351.96 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $334.28 | 2021-2023 | Steglatro |
| Tandem Diabetes Care, INC. | $298.44 | 2021-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals LP | $269.40 | 2021-2023 | Farxiga |
| Amarin Pharma, INC. | $216.63 | 2021-2022 | |
| Alfasigma USA, INC. | $160.85 | 2022 | |
| Corcept Therapeutics | $151.21 | 2021-2023 | Korlym |
| Medtronic, INC. | $137.99 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2022 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $119.87 | 2021-2024 | Tepezza, Repatha, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $112.27 | 2022-2023 | |
| Abbott Laboratories | $99.88 | 2021-2023 | Freestyle Libre 3, Proclaim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.66 | 2021 | |
| Antares Pharma, INC. | $92.00 | 2022-2023 | Xyosted, Tlando, Nocdurna |
| Amneal Pharmaceuticals LLC | $74.62 | 2021-2023 | Unithroid |
| Arbor Pharmaceuticals, INC. | $70.09 | 2021-2022 | |
| Pfizer INC. | $69.98 | 2021-2025 | |
| Galderma Laboratories, L.P. | $63.61 | 2025 | Nemluvio |
| Azurity Pharmaceuticals, INC. | $49.14 | 2023 | Triptodur |
| Glaxosmithkline, LLC. | $46.47 | 2023 | Shingrix, Arexvy |
| Zealand Pharma US, INC. | $45.53 | 2021-2022 | |
| Ascendis Pharma Endocrinology INC | $37.32 | 2022 | |
| Halozyme INC | $37.08 | 2023 | |
| Almirall LLC | $35.56 | 2025 | Seysara, Klisyri |
| Cequr Corporation | $35.43 | 2023-2025 | Cequr Simplicity |
| Xeris Pharmaceuticals, INC. | $35.39 | 2022-2023 | Recorlev |
| Ibsa Pharma INC. | $32.70 | 2021 | |
| Organon LLC | $31.32 | 2025 | Vtama, Nexplanon |
| Organogenesis INC. | $30.34 | 2021-2022 | |
| Tolmar, INC. | $24.89 | 2023 | |
| Horizon Therapeutics Plc | $23.23 | 2023 | Tepezza |
| Ipsen Biopharmaceuticals, INC | $22.68 | 2022 | |
| Radius Health, INC. | $18.89 | 2022 | |
| Beta Bionics, INC. | $18.60 | 2023 | Ilet Bionic Pancreas |
| Insulet Corporation | $18.07 | 2023 | Omnipod |
| Endo Pharmaceuticals INC. | $16.64 | 2021 | |
| Alexion Pharmaceuticals, INC. | $16.63 | 2021 | |
| Eusa Pharma (US) LLC | $15.89 | 2022 | |
| Recordati_rare_diseases_inc. | $15.89 | 2022 | |
| Amryt Pharma Holdings LTD | $15.06 | 2022 | |
| Dermavant Sciences, INC. | $14.22 | 2024 | Vtama |
| Tolmar Pharmaceuticals, INC. | $12.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.